ClinicalTrials.gg

Program

NNC0519-0130

A development code. Also written as “NNC0519-0130 B” and “NNC0519-0130 C”.

In Novo Nordisk's own words, a once-weekly GIP/GLP-1 co-agonist (NNC0519-0130). Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Renal Insufficiency, Chronic · Diabetes Mellitus, led by Novo Nordisk.

Furthest: phase 2, since Mar 16, 202411 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk111 open or runningphase 2since Mar 16, 2024Apr 18, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 18, 2022First study: phase 1 study in Diabetes MellitusFirst studyNCT05363774 · 161 enrolled · Denmark, Germany
  2. May 12, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05870670 · 22 enrolled · Japan
  3. Mar 16, 20242 phase 2 studiesNCT06326060, NCT06326047
  4. Apr 12, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06370819 · 36 enrolled · Germany
  5. Jul 16, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06513104 · 47 enrolled · Germany
  6. Aug 20, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06567041 · 82 enrolled · Germany
  7. Oct 13, 2024Phase 1 study in ObesityNCT06642571 · 46 enrolled · United States
  8. Nov 30, 2024Phase 2 study in Renal Insufficiency, ChronicNCT06717698 · 465 planned · United States, Argentina, Australia and more
  9. Dec 2, 2024Phase 1 study in ObesityNCT06718998 · 134 enrolled · Austria
  10. May 26, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07004322 · 20 enrolled · China

TargetBeta

“a once-weekly GIP/GLP-1 co-agonist (NNC0519-0130)”company filing, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
TirzepatideruleEli Lillyphase 472
retatrutideruleEli Lillyphase 333
olatorepatideHansoh Pharmaceutical Groupphase 312
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
VK2735ruleViking Therapeuticsphase 38
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07004322Diabetes Mellitus, Type 2 · China1CompletedJan 28, 202620
NCT06718998Obesity · Austria1CompletedJan 12, 2026134
NCT06717698Renal Insufficiency, Chronic · United States, Argentina, Australia and more2RecruitingSep 1, 2026465
NCT06642571Obesity · United States1CompletedMay 17, 202546
NCT06567041Diabetes Mellitus, Type 2 · Germany1CompletedDec 10, 202582
NCT06513104Diabetes Mellitus, Type 2 · Germany1CompletedSep 10, 202547
NCT06370819Diabetes Mellitus, Type 2 · Germany1CompletedNov 27, 202436
NCT06326060Obesity · United States, Australia, Japan2CompletedApr 10, 2025354
NCT06326047Diabetes Mellitus, Type 2 · United States, Australia, Canada and more2CompletedSep 19, 2025299
NCT05870670Diabetes Mellitus, Type 2 · Japan1CompletedOct 7, 202322
NCT05363774Diabetes Mellitus · Denmark, Germany1CompletedApr 2, 2024161

How it is read

Names in the registry

  • “NNC0519-0130”, 10 entries
  • “NNC0519-0130 B”, 1 entry
  • “NNC0519-0130 C”, 1 entry

Codes read as this program: NNC05190130.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.